# Gavin Thurston

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gavin-thurston/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,486 |
| Field | Angiogenesis and VEGF in Cancer |
| h-index | 79 |
| i10-index | 156 |
| Last Known Institution | Regeneron (United States) |
| OpenAlex ID | https://openalex.org/A5015053419 |
| ORCID iD | https://orcid.org/0000-0002-4105-5919 |
| Works | 486 |

## Researcher papers

- [Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation](https://scholariq.org/papers/angiopoietin-2-sensitizes-endothelial-cells-to-tnf-and-has-a-crucial-role-in-the/)
- [Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting](https://scholariq.org/papers/delta-like-ligand-4-dll4-is-induced-by-vegf-as-a-negative-regulator-of/)
- [Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma](https://scholariq.org/papers/intratumoral-dendritic-cell-cd4-t-helper-cell-niches-enable-cd8-t-cell/)
- [Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification](https://scholariq.org/papers/single-cell-analysis-of-human-non-small-cell-lung-cancer-lesions-refines-tumor/)
- [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial](https://scholariq.org/papers/cemiplimab-in-locally-advanced-basal-cell-carcinoma-after-hedgehog-inhibitor/)
- [Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial](https://scholariq.org/papers/neoadjuvant-cemiplimab-for-resectable-hepatocellular-carcinoma-a-single-arm-open/)

## Researcher topics

- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Regeneron (United States)](https://scholariq.org/institutions/regeneron-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.